🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2023-503573-38-00
Authorised Phase I

Safety of stem cells in treatmemt of retinal diseases.

2023-503573-38-00 · tracked via the Priya Life Science EU tracker
Sponsor
Bioinova a.s.
Sponsor type
Pharmaceutical company
Therapeutic area
Eye Diseases
Decision date
28/04/2026
Enrollment target
10
Sites
Czechia

Condition studied

Retinal degenerative diseases

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2023-503573-38-00 on CTIS ↗ ← All trials in the EU